Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial.

IL-19 and beta-defensin expression were also strongly correlated with each other ( r = 0.81) and highly significant ( P < 0.0001), suggesting that both biomarkers are involved in the same pathway of psoriasis pathogenesis.

also in 132,142 other papers